Real Tech Fund Invests in TOMOCLOUD, Developer of Non-Invasive Bio-Imaging Equipment

UntroD Capital Japan Co., Ltd. (Location: Minato-ku, Tokyo; Representative: Akihiko Nagata) announces that the Real Tech Fund* it operates has invested in TOMOCLOUD Co., Ltd. (Headquarters: Chiba City, Chiba Prefecture; Representative Director: Ryoma Ogawa; hereinafter "TOMOCLOUD"), a company developing non-invasive bio-imaging equipment using Electrical Impedance Tomography (EIT) technology. Using the funds raised this time, TOMOCLOUD will promote the social implementation of early detection and continuous monitoring of edematous conditions, including lymphedema.

Company Overview

TOMOCLOUD Co., Ltd. is a startup originating from Chiba University, founded in August 2025, aiming to realize a society where everyone can live true to themselves through next-generation visualization technology: Electrical Impedance Tomography (EIT). Starting with the early detection and monitoring of "edema," including lymphedema, the company aims to build a platform that can expand to the visualization of multiple diseases and body parts in the medical, healthcare, and nursing care fields in the future.

Purpose and Use of Funds Raised

TOMOCLOUD received investment from the Real Tech Fund, raising 50 million yen. These funds will be used to advance preparations for non-clinical trials and development for practical use of devices for medical institutions, as well as to accelerate the development of prototypes for home use.

Comment from the Responsible Person

We perceive the vision "visualizing the invisible" advocated by TOMOCLOUD as the very essence of how medicine has evolved. For example, blood pressure became something that could be measured, grasped as a numerical value, and routinely monitored. Similarly, in the case of lymphedema, quantifying a condition that was previously "not numerically expressed" and enabling its continuous monitoring is extremely innovative. The Real Tech Fund will support TOMOCLOUD's challenge to create new medical infrastructure that enables the assessment of not only the "quantity of edema" but also the "quality of edema" through its proprietary technology, leading to treatment choices and early intervention. (Hiromi Hiraizumi, Growth Manager, UntroD Capital Japan Co., Ltd.) *Official name: "Real Tech Fund No. 4 Investment Business Limited Partnership"

About TOMOCLOUD Co., Ltd.

About UntroD Capital Japan Co., Ltd. and the Real Tech Fund

UntroD Capital Japan Co., Ltd. established the "Real Tech Fund" in 2015 with the aim of socially implementing deep tech startups possessing innovative technologies that contribute to solving challenges for the Earth and humanity, and has since led investments and provided hands-on support to seed and early-stage startups. To date, it has managed Real Tech Funds No. 1 to No. 4 (Japan Funds), Real Tech Global Funds No. 1 and No. 2 (Global Funds), Real Tech Growth Fund No. 1 (Japan Fund), and the Crossover Impact Fund (Japan Fund), with total assets under management exceeding 40 billion yen. To further embody its commitment to being the first to step into uncharted territories necessary for society where capital is scarce, proving their economic viability to create a sustainable mechanism for continuous supply of capital and talent, the company restarted in June 2024 under the name "UntroD," meaning "untrodden." https://untrod.inc HP: https://untrod.inc

Contact

UntroD Capital Japan Co., Ltd. Public Relations Contact: Narita https://untrod.inc/contact https://untrod.inc/contact